Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in...

Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or...

Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...

Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...

Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for...